Targeted Therapy Directed by Genetic Testing in Advanced Refractory Solid Tumors or Lymphomas
This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
Patients undergo biopsy along with molecular characterization of the biopsy material for specific, pre-defined mutations, amplifications, or translocations of interest via tumor sequencing and immunohistochemistry. Consenting patients also undergo collection of blood samples for research purposes.
Patients are assigned to 1 of 24 treatment subprotocols based on molecularly-defined subgroup. Patients experiencing disease progression on the prior Step treatment or who could not tolerate the assigned treatment undergo review of their previous biopsy results to determine if another treatment is available or undergo another biopsy. Patients may have a maximum of 2 screening biopsies and 2 treatments per biopsy.
Consenting patients undergo end-of-treatment biopsy and collection of blood samples for research purposes. After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 1 year.
- Bladder Cancer
- Brain and Nervous System
- Breast Cancer
- Colon Cancer
- Gastrointestinal Cancer
- Gynecologic Cancer
- Head & Neck Cancer
- Kidney Cancer (Renal Cell)
- Liver Cancer
- Lung Cancer
- Lymphoma - Hodgkin
- Lymphoma - Non-Hodgkin
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
- Skin Cancer
- Urologic Cancer
Keywordsrefractory cancers, Therapy Choice, Molecular Analysis, lymphoma, MATCH
Principal InvestigatorThomas J George, Jr, M.D.
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.